ESR2 and breast cancer: Initially, low ERβ protein levels in ERα-positive tumors were reported to predict resistance to tamoxifen [105,106], and treatment of breast cancer cells with ERβ-selective agonists enhanced the growth-inhibitory effects of tamoxifen [107–109].